On Monday, Baird maintained a positive stance on Biohaven Pharmaceutical Holding (NYSE:BHVN) shares, reiterating an Outperform rating and a price target of $60.00. The optimism is due to encouraging clinical results from a competitor, which could have favorable implications for Biohaven's product in development.
The competitor, Scholar Rock, reported a significant victory for myostatin inhibitors used in treating neuromuscular diseases. Their drug, apitegromab, showed a statistically significant improvement over placebo in patients with Spinal Muscular Atrophy (SMA) who were already taking other medications, nusinersen or risdiplam. The response of Scholar Rock's stock to these results suggests that the market had previously undervalued the potential of myostatin inhibitors in this domain.
Baird anticipates that Biohaven could see similar success with its own myostatin inhibitor, taldefgrobep alfa, which is currently in development. A Phase 3 topline readout for the drug is expected in the second half of 2024. The firm believes that the subcutaneous administration method of taldefgrobep alfa, as opposed to the intravenous method required for apitegromab, could offer an additional advantage for Biohaven in the market.
The outcome of the Phase 3 study is eagerly awaited as it will provide more clarity on taldefgrobep alfa's efficacy and potential market position in treating SMA. Biohaven's current valuation reflects the market's anticipation for these developments.
In other recent news, Biohaven Pharmaceutical Holding has seen a flurry of positive developments. BofA Securities raised Biohaven's price target to $63 on the back of a promising study update on the company's troriluzole treatment for spinocerebellar ataxia (SCA). JPMorgan (NYSE:JPM) also increased its price target for Biohaven to $68, maintaining an Overweight rating, following announcements about the same troriluzole program.
Biohaven plans to re-file its New Drug Application in late 2024, with potential approval around mid-2025. If approved, troriluzole could achieve peak U.S. sales of over $1.5 billion, according to analysts.
Biohaven has also initiated a public offering of its common shares, potentially reaching gross proceeds of approximately $250 million. Additionally, the company has launched a pivotal Phase 2 study for its new migraine treatment, BHV-2100, after encouraging results in Phase 1 trials.
Furthermore, Biohaven plans to file for approval for its lead candidate, BHV-1300, following FDA approval for Multiple Ascending Dose studies in Rheumatoid Arthritis patients. TD (TSX:TD) Cowen maintained its Buy rating and a $55.00 price target for Biohaven, reflecting optimism about the company's clinical developments. Other analyst firms such as Leerink Partners and H.C. Wainwright also maintained positive ratings and increased their price targets for Biohaven.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Biohaven Pharmaceutical Holding's financial position and market performance, providing context to Baird's optimistic outlook. The company's market capitalization stands at $4.81 billion, reflecting investor confidence in its potential.
Notably, Biohaven has demonstrated impressive stock performance, with a 98.29% price total return over the past year. This aligns with the positive sentiment surrounding the company's pipeline, particularly the anticipated Phase 3 readout for taldefgrobep alfa.
However, it is important to note that Biohaven is currently operating at a loss, with an adjusted operating income of -$781.27 million for the last twelve months as of Q2 2024. This is not unusual for biotech companies in the development stage, and investors are likely focusing on the potential of Biohaven's pipeline rather than current profitability.
InvestingPro Tips highlight that Biohaven "holds more cash than debt on its balance sheet" and has "liquid assets exceed[ing] short term obligations," which could provide financial flexibility as the company advances its clinical programs. These factors may contribute to the company's ability to fund ongoing research and development, including the crucial taldefgrobep alfa study.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Biohaven Pharmaceutical Holding, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.